Prostate cancer (PCa) remains a significant health concern impacting millions of men around the globe. Screening, diagnosis, and treatment of PCa have improved significantly over the past few years. In recent years, advancements in modern imaging technology have enhanced early and initial diagnosis, as well as the detection of distant metastases and recurrences.In recent years, there have been notable advancements in contemporary imaging methodologies, leading to substantial improvements in the detection and diagnostic assessment of PCa, thus advancing patient care. Multiparametric MRI and MR/TRUS fusion biopsy have enhanced initial detection and prognosis stratification, while prostate-specific membrane antigen hybrid imaging has enhanced staging and the identification of cancer recurrence, especially in high- risk individuals. The utilization of mpMRI is becoming increasingly widespread and rapidly integrated into routine clinical practice for risk stratification of lesions suspected of clinically significant PCa, assessment of the local-regional extent and staging of identified lesions, treatment planning, and patient management. In this section, an overview of imaging methods for PCa treatment will be presented based on the literature.